336 related articles for article (PubMed ID: 1511458)
21. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
22. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
24. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
25. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
Ebihara T; Fukao K; Koyama S
Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
[TBL] [Abstract][Full Text] [Related]
26. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Pendurthi TK; Schlom J; Primus FJ
J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
[TBL] [Abstract][Full Text] [Related]
27. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
28. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
29. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
[TBL] [Abstract][Full Text] [Related]
31. Activated natural killer cells suppress myelopoiesis in mice with severe combined immunodeficiency.
Pisa P; Sitnicka E; Hansson M
Scand J Immunol; 1993 Apr; 37(4):529-32. PubMed ID: 8469936
[TBL] [Abstract][Full Text] [Related]
32. Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.
Hasui M; Saikawa Y; Miura M; Takano N; Ueno Y; Yachie A; Miyawaki T; Taniguchi N
Cell Immunol; 1989 Apr; 120(1):230-9. PubMed ID: 2784720
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
34. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
[TBL] [Abstract][Full Text] [Related]
35. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
38. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
39. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
40. Effects of low dose total body irradiation (LDTBI) and recombinant human interleukin-2 in mice.
Fourquet A; Teillaud JL; Lando D; Fridman WH
Radiother Oncol; 1993 Mar; 26(3):219-25. PubMed ID: 8316651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]